Antitumor activity of tipifarnib and PI3K pathway inhibitors in HRAS-associated head and neck squamous cell carcinoma. (October 2020) - Burrows, F.; Shivani, M.; Wang, Z.; Chan, S.; Gilardi, M.; Gutkind, S.